Alcohol-Associated Hepatitis Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Alcohol-Associated Hepatitis remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 45 matched trial records and 51 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| JPRN-UMIN000061896 | Intervention not normalized | Not Applicable; 一般募集中/Open public recruiting | Kagawa University | Japan | ADH1B低活性×ALDH2活性の遺伝子型とSAH発症の関連 ; Association between ADH1B low-activity / ALDH2 active genotype and the onset of severe alcoholic hepatitis (SAH) | 2028-09-30 |
| NCT07465588 | Intervention not normalized | Not Applicable; Not yet recruiting | The Massachusetts General Hospital | Geography not listed | Alcohol Abstinence Measured by PEth (12 weeks) | 2028-03-31 |
| NCT07428538 | Larsucosterol | Phase 3; Recruiting | Bausch Health Americas, Inc. | United States | Transplant Free Survival up to Day 90 (Up to Day 90) | 2027-11-01 |
| NCT07262515 | Intervention not normalized | Not Applicable; Recruiting | Assistance Publique des Hôpitaux de Paris SA | France | Overall survival after diagnosis of acute alcoholic hepatitis (From diagnosis up to 7 years after) | 2025-12-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules (Phase 2): the indexed record reports MELD score = Relative to baseline, statistically significant improvement was observed in clinically relevant objective markers of hepatic function and inflammation, including the Model for End-Stage Liver Disease (MELD) score (P=0.001).
- IL-1 Signal Inhibition in Alcoholic Hepatitis (ISAIAH) (Phase 2): the indexed record reports Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline. = 10 Participants; Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline.: Mean Difference (Net) = 16.7(95% CI, -11.2 to 44.5), P-Value = 0.248; Number of Patients Presenting Histological Improvement of Alcoholic Hepatitis on Liver Biopsy After 28 Days of Treatment Compared to Baseline.: Mean Difference (Net) = 16.7(95% CI, -11.2 to 44.5), P-Value = 0.248.
- Effect of terlipressin on patients with hepatorenal syndrome, alcohol-associated hepatitis, and acute-on-chronic liver failure grade 0–2 (Phase 3): the indexed record reports HRS reversal = 11.7 %; HRS reversal = 44.0 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Larsucosterol (Phase 3; DNMTs). Company & Deal Intelligence records identify sponsor context for Kagawa University, The Massachusetts General Hospital, Bausch Health Americas, Inc. (VRX), Assistance Publique des Hôpitaux de Paris SA. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Alcohol-Associated Hepatitis has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
